GlassScriptPhysician profile
Ema Kulwa
NPI 1528299278
$10,898.08
in general payments reported to CMS, 2019-2025
30 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $207 · 2021: $682 · 2022: $462 · 2023: $597 · 2024: $7,092 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Travel and Lodging: $2,108 · Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Travel and Lodging | $2,107.79 |
| Food and Beverage | $1,249.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,174.93 | 2024-2025 | |
| Abbvie INC. | $1,117.08 | 2019-2025 | |
| Medtronic, INC. | $310.49 | 2023 | Ligasure |
| Astellas Pharma US INC | $184.86 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $150.07 | 2019-2023 | Injectafer |
| Hologic Sales and Service, LLC | $137.59 | 2024-2025 | Myosure Tissue Removal Device, Coolseal Generator, Aptima |
| Biogen, INC. | $77.04 | 2025 | Zurzuvae |
| Medline Industries LP | $75.77 | 2022 | |
| Exeltis, USA INC. | $72.24 | 2021-2023 | Slynd |
| Novo Nordisk INC | $67.76 | 2019-2024 | Wegovy |
| Evofem Biosciences, INC. | $66.83 | 2021-2025 | Phexxi, Solosec, Phexx |
| Myovant Sciences INC. | $49.14 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $48.61 | 2023-2024 | Myfembree |
| Merck Sharp & Dohme LLC | $41.39 | 2019-2021 | |
| Aspira Women'S Health INC | $37.80 | 2022-2024 | Ova1 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $37.23 | 2021 | |
| Allergan, INC. | $31.93 | 2019-2020 | |
| Therapeuticsmd, INC. | $28.49 | 2020-2022 | |
| Kerecis Limited | $28.13 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Pfizer INC. | $26.86 | 2022-2023 | |
| Organon LLC | $18.93 | 2023 | Nexplanon |
| Gynesonics, INC. | $17.12 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Lupin INC. | $16.69 | 2020 | |
| Meditrina | $15.50 | 2024 | |
| Shield Therapeutics INC | $14.93 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.98 | 2020 | |
| Sanofi Pasteur INC. | $13.58 | 2025 | |
| Medicem INC. | $11.95 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ema Kulwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.